OMAR LONGORIA: Open Payments
NPI 1952061988 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,155 in 55 payments from 13 companies in 2025. Trend: 2023 $597 · 2024 $914 · 2025 $5,155
Consulting: $2,450Food & beverage: $1,597Travel & lodging: $1,108
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 14 | $4,249 |
| Novo Nordisk Inc | 17 | $415 |
| AstraZeneca Pharmaceuticals LP | 5 | $99 |
| Astellas Pharma US Inc | 4 | $90 |
| ABBVIE INC. | 5 | $70 |
| Lilly USA, LLC | 2 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| JAZZ PHARMACEUTICALS INC. | 1 | $38 |
| ViiV Healthcare Company | 1 | $30 |
| Bioventus LLC | 1 | $21 |
Products named: Yeztugo, Ozempic, AIRSUPRA, Veozah, UBRELVY, JARDIANCE, GEMTESA, EPIDIOLEX.
Industry payments across TX — which companies pay providers there.
